Meta-analysis of six randomized control trials of chemotherapy plus anti-HER monoclonal antibody for advanced gastric and gastroesophageal cancer

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 13, 2014, Pages 5343-5348

  Luo, Huai Qing ^a   Han, Li ^a   Jiang, Yan ^a  

^a CHANGSHA MEDICAL UNIVERSITY   (China)

Author keywords

Chemotherapy; EGFR antibody; Gastric and gastroesophageal cancer; Meta analysis; Trastuzumab

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ANTAGONISTS AND INHIBITORS; DISEASE FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; FEMALE; HUMAN; MALE; META ANALYSIS; MIDDLE AGED; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK; STOMACH NEOPLASMS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, ERBB-2; RISK; STOMACH NEOPLASMS;

EID: 84905390000     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.13.5343     Document Type: Article

References (48)

1. Ajani JA (2006). Chemotherapy for advanced gastric or gastroesophageal cancer: defining the contributions of docetaxel. Expert Opin Pharmacother, 7, 1627-31.
2. Ajani JA, Baker J, Pisters PW, et al (2002). CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. Cancer, 94, 641-6.
3. Bang YJ, Van Cutsem E, Feyereislova A, et al (2010). Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet, 376, 687-97.
4. Begg CB, Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics, 50, 1088-101.
5. Butts CA, Bodkin D, Middleman EL, et al (2007). Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. J Clin Oncol, 25, 5777-84.
6. Cai Y, Wang JY, Liu H (2013). Clinical observation of whole brain radiotherapy concomitant with targeted therapy for brain metastasis in non-small cell lung cancer patients with chemotherapy failure. Asian Pac J Cancer Prev, 14, 5699-703.
7. Colevas AD, Setser A (2004). The NCI Common Terminology Criteria for Adverse Events (CTCAE) v 3.0 is the new standard for oncology clinical trials.
8. Crosby T, Hurt CN, Falk S, et al (2013). Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. Lancet Oncol, 14, 627-37.
9. Douillard JY, Siena S, Cassidy J, et al (2010). Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol, 28, 4697-705.
10. Douillard JY, Siena S, Cassidy J, et al (2010b). Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol, 28, 4697-705.
11. Egger M, Davey SG, Schneider M, et al (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34.
12. Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917.
13. Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, et al (2013). 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet, 382, 1021-8.
14. Hirono Y, Tsugawa K, Fushida S, et al (1995). Amplification of epidermal growth factor receptor gene and its relationship to survival in human gastric cancer. Oncology, 52, 182-8.
15. Hoag JB, Azizi A, Doherty TJ, et al (2009). Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review. J Exp Clin Cancer Res, 28, 113.
16. Huang S, Armstrong EA, Benavente S, et al (2004). Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res, 64, 5355-62.
17. Ibrahim EM, Abouelkhair KM, Al-Masri OA, et al (2011). Cetuximab-based therapy is effective in chemotherapy-naive patients with advanced and metastatic non-small-cell lung cancer: a meta-analysis of randomized controlled trials. Lung, 189, 193-8.
18. Jadad AR, Moore RA, Carroll D, et al (1996). Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials, 17, 1-12.
19. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
20. Lacouture ME, Melosky BL (2007). Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspective. Skin Therapy Lett, 12, 1-5.
21. Lenz HJ (2006). Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events. Oncology, 20, 5-13.
22. Li W, Qin J, Sun YH, et al (2010). Neoadjuvant chemotherapy for advanced gastric cancer: a meta-analysis. World J Gastroenterol, 16, 5621-8.
23. Li X, Shan BE, Wang J, et al (2013). Incidence and risk of treatment-related mortality with anti-epidermal growth factor receptor monoclonal antibody in cancer patients: a meta-analysis of 21 randomized controlled trials. PLoS One, 8, 81897.
24. Lordick F, Kang YK, Chung HC, et al (2013). Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol, 14, 490-9.
25. Mendelsohn J, Baselga J (2003). Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol, 21, 2787-99.
26. Moher D, Liberati A, Tetzlaff J, et al (2010). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg, 8, 336-41.
27. Nordlinger B, Sorbye H, Glimelius B, et al (2013). Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol, 14, 1208-15.
28. Olayioye MA, Neve RM, Lane HA, et al (2000). The ErbB signaling network: receptor heterodimerization in development and cancer. Embo J, 19, 3159-67.
29. Parmar MK, Torri V, Stewart L (1998). Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med, 17, 2815-34.
30. Perez EA, Suman VJ, Davidson NE, et al (2008). Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol, 26, 1231-8.
31. Pozzo C, Barone C, Szanto J, et al (2004). Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin.in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study. Ann Oncol, 15, 1773-81.
32. Rao S, Starling N, Cunningham D, et al (2010). Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients.with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study. Ann Oncol, 21, 2213-9.
33. Rosell R, Robinet G, Szczesna A, et al (2008). Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann Oncol, 19, 362-9.
34. Sakuramoto S, Sasako M, Yamaguchi T, et al (2007). Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med, 357, 1810-20.
35. Sasako M (2003). Principles of surgical treatment for curable gastric cancer. J Clin Oncol, 21, 274s-275s.
36. Sawaki A, Ohashi Y, Omuro Y, et al (2012). Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study. Gastric Cancer, 15, 313-22.
37. Segaert S, Van Cutsem E (2005). Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol, 16, 1425-33.
38. Shen L, Xu JM, Feng FY, et al (2013). Trastuzumab in combination with chemotherapy versus chemotherapy alone for first-line treatment of HER2-positive advanced gastric or gastroesophageal junction cancer: a phase III, multi-center, randomized controlled trial, Chinese subreport. Zhonghua Zhong Liu Za Zhi, 35, 295-300 (in Chinese).
39. Slamon DJ, Clark GM, Wong SG, et al (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235, 177-82.
40. Tabernero J (2007). The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res, 5, 203-20.
41. Van Cutsem E, Kohne CH, Hitre E, et al (2009). Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med, 360, 1408-17.
42. Waddell T, Chau I, Cunningham D, et al (2013). Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol, 14, 481-9.
43. Wagner AD, Grothe W, Haerting J, et al (2006). Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol, 24, 2903-9.
44. Yarden Y, Sliwkowski MX (2001). Untangling the ErbB signalling network. Nat Rev Mol Cell Biol, 2, 127-37.
45. Ychou M, Boige V, Pignon JP, et al (2011). Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol, 29, 1715-21.
46. Yonemura Y, Sugiyama K, Fujimura T, et al (1989). Epidermal growth factor receptor status and S-phase fractions in gastric carcinoma. Oncology-Basel, 46, 158-61.
47. Zeng C, Zhou H, Wei Y, et al (2014). Chemotherapy with or without irinotecan in patients with advanced or recurrent gastric cancer: a meta-analysis of randomized controlled trials. Chin Med J, 127, 951-6.
48. Zhang E, Cao W, Cheng C, et al (2014). A systemic analysis of s-1 regimens for treatment of patients with colon cancer. Asian Pac J Cancer Prev, 15, 2191-4.